Carnot CALYM
The Consortium for the Acceleration of Innovation and its Transfer in the Lymphoma Field
The CALYM Carnot Institute fosters together 20 research teams specialized in lymphoma, first blood cancer. This academic consortium, without international equivalent, aims at accelerating innovation and its transfer in the lymphoma treatment and diagnosis through a unique R&D offer spanning from the identification of new biological targets to registration clinical trials.
Key figures
Fermer
Key figures
| Permanent staff (full-time equivalent) | 337 |
| PhD Students | 58 |
| Global budget | 32 M€ |
| Partnership incomes with industry | 28,2 M€ |
Contact
Fermer
Contact
institut Carnot CALYM
Centre Hospitalier Lyon-Sud
69495 Pierre-Bénite Cedex
Bertrand NADEL
Director
+33(0)4 72 24 41 71
+33(0)7 63 79 13 40
bertrand.nadel[a]calym.org Email contact
partnering[a]calym.org
Parent institutions
Fermer
Parent institutions
- AIX-MARSEILLE UNIVERSITÉ
- AP-HP ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS
- CENTRE HENRI BECQUEREL
- CENTRE LÉON BÉRARD
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
- CHU DE MONTPELLIER
- CHU DE NANTES
- CHU DE RENNES
- CHU DE TOULOUSE
- EFS BRETAGNE
- HOSPICES CIVILS DE LYON
- INSERM
- INSTITUT CLAUDIUS REGAUD - INSTITUT UNIVERSITAIRE DU CANCER TOULOUSE - ONCOPOLE
- INSTITUT GUSTAVE ROUSSY
- INSTITUT NECKER
- INSTITUT PAOLI-CALMETTES
- IRCCS
- LYSA
- LYSARC
- UNIVERSITÉ CLAUDE BERNARD LYON 1
- UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS
- UNIVERSITÉ DE LIMOGES
- UNIVERSITÉ DE MONTPELLIER
- UNIVERSITÉ DE RENNES 1
- UNIVERSITÉ DE ROUEN NORMANDIE
- UNIVERSITÉ PARIS DESCARTES
- UNIVERSITÉ PARIS SUD
- UNIVERSITÉ PARIS-EST CRÉTEIL
- UNIVERSITÉ TOULOUSE 3
Présentation
A Carnot Institute Devoted to Lymphoma: creating synergies, initiating partnerships, accelerating translational research
Target markets
- Pharmaceutic industry
- Biotechnologies
- In vitro diagnosis
- Imaging
- Artificial Intelligence
Our 4 R&D Pillars at the Core of Innovation
 |
1. Research and validation of new biological targets and lymphoma in vitro and in vivo models > to develop new preclinical drug candidates |
 |
2. Identification, validation, patenting and licensing of blood and tissue biomarkers > to improve diagnosis, guide therapy decisions and predict tumor responses |
 |
3. Early monitoring of activity (early pharmacodynamic markers, circulating DNA, immunomonitoring) > to accelerate translational research |
 |
4. Optimization and exploitation of clinical research related tools > to accelerate development, registration and market access of drug candidates |
Consortium overview
20 multidisciplinary and complementary research entities in the lymphoma field:
- LYSA: The Lymphoma Study Association, a cooperative group
- LYSARC: The Lymphoma Academic Research Organisation
- 18 academic research teams (belonging to Inserm or CNRS national research bodies, to universities and/or to hospitals)
CALYM is certified ISO 9001:2015
for the management and monitoring of its research activities
and for its coordination of viable cell collection - CeVi
CALYM is member of FINDMED
www.findmed.fr
